Clinical Trial Update: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the 13-valent pneumococcal conjugate vaccine (Prevnar 13) in healthy infants has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Vaccines, Pneumococcal Conjugate Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2010-06-04